BridgeBio Pharma: Pay

BridgeBio Pharma paid its 3 named executives $27.7M in total in FY2024 (Dec). CEO Neil Kumar, Ph.D. was paid $15.6M of that.

Pay$100 in the stock at the end of FY20 → $39
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Neil Kumar, Ph.D.Chief Executive Officer
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Thomas Trimarchi, Ph.D.President and Chief Financial Officer
FY2024 (Dec)
1 year
Brian Stephenson, Ph.D., CFAFormer Chief Financial Officer
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $21.2M. The CEO of BridgeBio Pharma was paid $14.9M, 29% below the median.

  1. 1Exelixis
  2. 2Incyte
  3. 3PTC Therapeutics
  4. 4Halozyme Therapeutics
  5. 5Madrigal Pharmaceuticals
  6. 6BridgeBio Pharma
  7. 7Ionis Pharmaceuticals
  8. 8Ultragenyx Pharmaceutical
  9. 9Neurocrine Biosciences
  10. 10Acadia Pharmaceuticals Inc.Not disclosed
  11. 11Amicus Therapeutics, Inc.Not disclosed
  12. 12Apellis Pharmaceuticals, Inc.Not disclosed
  13. 13Arrowhead Pharmaceuticals, Inc.Not disclosed
  14. 14BioMarin Pharmaceuticals Inc.Not disclosed
  15. 15Biohaven Ltd.Not disclosed
  16. 16Blueprint Medicines CorporationNot disclosed
  17. 17Cytokinetics, IncorporatedNot disclosed
  18. 18Iovance Biotherapeutics, IncNot disclosed
  19. 19Jazz Pharmaceuticals Public Limited CompanyNot disclosed
  20. 20Roivant SciencesNot disclosed
  21. 21Sarepta Therapeutics, Inc.Not disclosed
  22. 22SpringWorks Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.